|
Patent and Public Health:
Addressing the Future Imperatives of Health
Security in the Post-TRIPS Era
11 April
2005, New Delhi
Full
Report
As
per obligations under the Agreement on Trade Related Aspects of Intellectual
Property Rights (TRIPS) of the World Trade Organisation (WTO), from 1st
January 2005 onwards the product patent regime has been introduced in India
vide the Patent (Amendment) Act, 2005. Now product patent is enforced in all
sectors, including the pharmaceutical and agro-chemical sectors, which so far
had been out of such provisions. From the perspective of access to health,
the questions that arise are: Is India prepared to deal with the changed
situation? What should be the future course of action with respect to
manufacture, trade and procurement of generic drugs?
There
are law and policy tools that are available with the Government to deal with
adverse situation vis-ΰ-vis access to medicines, which may arise due to the
introduction of product patent regime. These include, among other things,
built-in safeguards in the Patents Act using the TRIPS flexibilities,
competition law and policy and drug price control regime. The questions that
need to be looked into are: How to implement these built-in safeguards; How
India should use competition law and policy to tackle adverse conditions with
respect to access to drugs which may arise due to introduction of product
patent regime? Does the new competition regime have such a scope? Is the
present drug price control regime effective and sufficient in controlling the
prices of patented drugs? etc.
The
Workshop aims to discuss the above-said issues amongst the stakeholders and
come out with suggestions that can shape an action plan to address future
challenges with respect to access to health, in the post-TRIPS era
Agenda
|
09.30 10.00 hrs
|
Registration
|
|
|
Inaugural Session
|
|
10.00 10.05 hrs
|
Welcome address by Shri B. P.
Sharma, Joint Secretary, Department of Health, Ministry of Health &
Family Welfare
|
|
10.05 10.20 hrs
|
Inaugural Address by Shri P.
Hota, Secretary, Department of Health, Ministry of Health & Family
Welfare
|
|
10.20 10.30 hrs
|
Address by Dr. S. J. Habayeb,
WHO Representative to IndiaAddress by Dr. S. J. Habayeb, WHO Representative to India
|
|
10.30 10.35 hrs
|
Vote of thanks by Shri Rajesh
Bhushan, Director (IH), Department of Health, Ministry of Health &
Family Welfare
|
|
|
|
|
|
|
Introductory Session
An overview of recent
law/policy developments on patents & public health
WTO Cell, Ministry of Health
& Family Welfare
|
|
11.00 11.30 hrs
|
Tea Break
|
|
|
Technical Session I
|
|
11.30 11.45 hrs
|
Manufacture of quality
generic drugs options available with Indian pharmaceutical sector and the
preparedness of the Indian pharmaceutical industry to deal with the changed
scenario
|
Shri Gajanan Wakankar,
Executive Director, Indian Drug Manufacturers Association, Mumbai
|
|
11.45 12.00 hrs
|
Para
6 of Doha Declaration and Indias response
|
Shri Narendra B. Zaveri,
Advocate, Mumbai
|
|
12.00 13.00 hrs
|
Open Discussion
|
|
|
|
13.00 14.00 hrs
|
Lunch Break
|
|
|
|
|
Technical
Session II
|
|
14.00 14.15 hrs
|
How
far the TRIPS-Flexibilities are being addressed in the Patent (Amendment)
Act, 2005?
|
Shri B. K. Keayla, Centre for
Study of Global Trade System and Development, New Delhi
|
|
14.15 14.30 hrs
|
Anti-competitive
practices in Patent Licensing Arrangements and the scope of competition
law/policy in dealing with them
|
Shri Anand Grover, AMTC,
Mumbai
|
|
14.30 14.45 hrs
|
WHO perspective on Patents and
Public Health
|
Dr. Weerasuriya, Regional
Adviser, EDM, WHO-SEARO
|
|
14.45 15.30 hrs
|
Open Discussion
|
|
|
|
|
|
|
15.30 16.00 hrs
|
Tea Break
|
|
|
|
|
|
|
|
Concluding Session - The Way Forward
|
|
16.00 16.45 hrs
|
Post-TRIPS scenario and Access
to Medicines: the way forward for India
·
Shri
Z.H. Charna, Director, Organisation of Pharmaceutical Producers of India
·
Shri
Ashwini Kumar, Drug Controller General of India, New Delhi
·
Shri Gurdeep Singh, Director,
Department of Chemicals and Petrochemicals, New Delhi
·
Shri Sunil Nandraj, WRI Office
|
|
16.45 17.15 hrs
|
Open
Discussions
|
|
17.15 17.30 hrs
|
Valedictory
& vote of thanks
|
|
|